Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System

Inclusion Criteria:

• Healthy female between the ages of 18 and 65
• Subject must be able to understand, read and sign the study specific informed consent forms after the nature of the study has been fully explained to her
• Subject is a pre-menopausal or peri-menopausal female, either nulliparous or parous
• Subject is indicated for myomectomy or polypectomy for benign pathology, based on hysteroscopic, ultrasound, or saline infused sonogram assessment within 60 days

• Subject exhibits intrauterine polyps and/or submucous myomas which meet one of the following criteria. In cases of subjects with multiple intrauterine pathology, classification is based as follows:

  • All polyps
  • A single Type 0 or Type 1 myoma ≤ 3 cm
  • Polyps plus a single Type 0 or Type 1 myoma ≤ 3 cm
• Negative pregnancy test within 48 hours prior to planned index procedure and willing to use reliable birth control for the next 30 days. Reliable birth control is defined as a chemical or barrier method, including an oral contraceptive, injectable contraceptive, or the combination of a spermicide and condoms

Exclusion Criteria:

• Known or suspected cancer, including breast, endometrial, and ovarian
• Subject has Type 2 myoma
• Contraindication and/or allergy to local anesthetic, or oral medications specified in the treatment protocol
• Subject has a history of chronic narcotic use
• Previous uterine artery embolization or other uterine artery occlusion procedure (Doppler or laparoscopic)
• Subject with blood borne pathogens-HIV, hepatitis B, CJD, etc.
• Subject plans to become pregnant within the study period
• Subject has an IUD at the time of the procedure. A subject may be enrolled in the study if the IUD is removed prior to the treatment procedure
• Subject is taking an anticoagulant or antiplatelet medication other than low dose aspirin
• Active pelvic inflammatory disease or pelvic/vaginal infection
• Subject has a known or suspected coagulopathy or bleeding disorder
• Subject has a history of unmanaged endocrine disease
• Subject has current or past, acute or chronic psychiatric disorder which, in the opinion of the Investigator, may preclude proper evaluation and follow-up
• Subject has history of auto-immune, inflammatory, or connective tissue disease
• Subject has a history of disease which increases the risk for fluid overload (i.e. significant cardiac, hepatic, or renal dysfunction)
• Uncontrolled hypertension lasting two years or more
• Use of any experimental drug or device within 30 days prior to the screening visit
• The subject has a terminal illness that may prevent the completion of any follow-up assessments
• Any employee or relative of an employee of the Sponsor company or any Investigator site employee or relative of employees working on the study
• Subject has other co-morbid condition(s) that, in the opinion of the Investigator, could limit the subject's ability to participate in the study or impact the scientific integrity of the study